LentiGlobin BB305: Additional Ph I/II HGB-206 data

Data from 7 evaluable patients with severe sickle cell disease in the open-label, U.S. Phase I/II HGB-206 trial showed that LentiGlobin BB305

Read the full 226 word article

User Sign In